Glucagon-Like Peptide-1-Based Therapies in Cardiovascular Disease: Evidence, Mechanisms, and Emerging Clinical Applications.
Glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed as glucose-lowering therapies for type 2 diabetes mellitus but have progressively emerged as cardiometabolic agents with clinically relevant cardiovascular effects. Large cardiovascular outcome trials have demonstrated reductions in major advers...